VALUATION AND QUALIFYING ACCOUNTS (Notes)

12 Months Ended

Dec. 31, 2025

SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]

VALUATION AND QUALIFYING ACCOUNTINGS

(In millions) For the years ended Dec 31,	2025		2024		2023
Accounts Receivable - Allowance for Doubtful Receivables
Balance at beginning of year	$	95	$	81	$	110
Additions charged to expenses 1	23		28		21
Deductions from reserves 2	(59)		(14)		(50)
Balance at end of year	$	59	$	95	$	81
Inventory - Obsolescence Reserve
Balance at beginning of year	$	88	$	70	$	57
Additions charged to expenses	14		27		20
Deductions from reserves 3	(2)		(9)		(7)
Balance at end of year	$	100	$	88	$	70
Reserves for Other Investments and Noncurrent Receivables
Balance at beginning of year	$	1,650	$	1,751	$	1,950
Additions charged to expenses 4	5		14		31
Deductions from reserves 5	(214)		(115)		(230)
Balance at end of year	$	1,441	$	1,650	$	1,751
Deferred Tax Assets - Valuation Allowance
Balance at beginning of year	$	2,748	$	2,948	$	1,269
Additions charged to expenses 6	633		55		1,864
Deductions from reserves	(331)		(255)		(185)
Balance at end of year	$	3,050	$	2,748	$	2,948

1.Additions included a $23 million reclassification from "Reserves for Other Investments and Noncurrent Receivables" in 2024.

2.Deductions included write-offs, recoveries, currency translation adjustments and other miscellaneous items, including a $23 million reclassification to "Reserves for Other Investments and Noncurrent Receivables" in 2023.

3.Deductions included disposals and currency translation adjustments.

4.Additions included a $23 million reclassification from "Accounts Receivable - Allowance for Doubtful Receivables" in 2023.

5.Deductions included $81 million related to the Company’s investment in DowAksa, which was converted to cash in 2025. See Note 4 to the Consolidated Financial Statements for additional information. Deductions also included a $23 million reclassification to "Accounts Receivable - Allowance for Doubtful Receivables" in 2024, $143 million related to the Company's investment in a previously held equity method investment, which was converted to cash, in 2023, and $77 million in 2025, 2024 and 2023 related to the Company's investment in Sadara. See Note 11 to the Consolidated Financial Statements for additional information.

6.Additions in 2023 include increases in valuation allowances related to foreign tax assets that are expected to expire without being utilized.